News | MLL

Our newsletter is an offer of MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich (“MLL,” “we”) and contains information about our products and services, research results, events and other news relevant to the company and to the discipline, especially regarding diagnostics and subsequent therapy for leukemia and lymphoma. For you to subscribe, we need the e-mail address that you want us to send the newsletter to. We may use optional information to personalize how the addressee is addressed.
To continuously improve the quality of our newsletter and its contents, we conduct a pseudonymized analysis of the opening rate of the newsletter and information on calling up specific articles. You can find detailed information on how personal data is processed in connection with our newsletter in our Data protection information section.

By clicking on the “Subscribe to the newsletter” button, I consent to allow MLL to use the e-mail address and optional information provided by me for sending the newsletter and for addressing me personally.

You have the right to withdraw your consent at any time. Withdrawing your consent does not affect the lawfulness of the processing that took place based on your consent up until the time of withdrawal. One way you can withdraw your consent is by using the withdrawal function contained in every newsletter. Alternatively, you can declare that you are withdrawing your consent by sending an e-mail to presse@remove-this.mll.com or by mailing a letter to MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich.

Here you will find all MLL News as well as scientific contributions to leukemia diagnostics and research.

to the MLL Magazine

Prof. Dr. med. Dr. phil. Torsten Haferlach
from 14.10.2021
Diagnostics
A Difficult Case: What the Diagnostics of Tomorrow Will Look Like
We have all learned: “Common things are common, except when the diagnosis is rare.” So far so good. Thanks to the large number of cases with increasingly networked data and by taking the current WHO classification as a basis, it is possible for even rare diagnoses to be assigned with greater precision today. This becomes more difficult, however, if the individual findings of the diagnostics chain and the blood values do not fit together in a conclusive way – or if any uncertainty simply remains even though the patient is definitely clinically ill. So what is the next step?
Post review
Current rating is 5.0 out of 5

1

2

3

4

5
Read article
PD Dr. med. Gregor Hörmann, PhD
from 15.10.2021
Automation & Artificial Intelligence
Good Findings Start with Preanalytics – Our Sample Receipt Introduces Itself
Every day, the MLL team focuses its combined efforts on making it possible for patients around the world to receive the best therapy thanks to quick and targeted leukemia diagnostics. But how does a normal workday look for the 200 or so employees? What are the different departments and areas? Our new magazine series “Introducing MLL” will be offering you a glimpse into our laboratory. In the first part, we want to present our Sample Receipt area.
Post review
Current rating is 4.5 out of 5

1

2

3

4

5
Read article